You are here
Aastrom Biosciences, Inc.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Clinical-scale Production of Osteoprogenitor Cells
Amount: $743,066.00DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Cells within the bone marrow are known to posses ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health -
Clinical Human Cell Production System for Broad Use
Amount: $798,266.00The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health -
Dendritic Cell Subset for Enhanced Cancer Vaccine
Amount: $109,586.00DESCRIPTION (provided by applicant): Tumor antigen primed dendritic cells (DCs) are under widespread clinical evaluation for immunotherapy of multiple forms of cancer. Emerging evidence suggests that ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Bioreactor for Enhanced T-cell Based Therapy of Melanoma
Amount: $124,154.00DESCRIPTION (provided by applicant): Malignant melanoma is a significant and deadly form of cancer worldwide. Emerging evidence has shown that melanoma cells express tumor-associated antigens that ar ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Clinical Human Cell Production System for Broad Use
Amount: $101,452.00DESCRIPTION (provided by applicant): As a result of growing evidence of their therapeutic potential in cancer, infectious diseases, and tissue repair, there is an enormous increase in the research an ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Enhanced Tumor Antigen Priming of Dendritic Cell Vaccine
Amount: $101,262.00DESCRIPTION (provided by the applicant): Dendritic cells have been shown to initiate, regulate, and direct cytolytic T-cell-mediated immune responses against tumor antigens in human patients. Recent ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Automated Perfused Culture Process for Adult Stem Cells
Amount: $442,555.00DESCRIPTION (provided by applicant): Adherent mesenchymal cell populations derived from bone marrow (BM) have the capability of differentiating into multiple cell lineages in vitro and in vivo. The po ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Clinical-scale Production of Osteoprogenitor Cells
Amount: $110,062.00DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Mixtures of marrow stromal cells (MSC) and carr ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Automated Large-Scale Production of Endothelial Cells
Amount: $99,840.00DESCRIPTION (provided by applicant): Treatment of ischemia by administration of bone marrow (BM)-derived endothelial progenitor cells (EPC) or ex vivo expanded EPC populations has been shown to enhanc ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
N/A
Amount: $0.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health